You are correct.
JT was an excellent bookkeeper.
He was however, a poor sales lead and a terrible hype man.
Hence stagnantion in sales and a lack of self promotion in the stock due to sandbagging and ultra conservatism.
A change is welcome indeed.
However, legal failures aside (which I blame on management in some part especially filing in the 9th circuit), management of the company has actually been reasonable.
Not good, but reasonable.
Without Du and Covid, i do believe Vascepa wales would have topped $1B or thereabouts in the US by run rate already. We certainly were on track pre covid.
Du debacle (insurers preferring generic or dropping coverage) and covid (fewer tests, less access to cardios and GPs) put paid to that.